FDA's Shocking Approval: Rexulti Fast-Tracked Despite Deadly Risks

Investigation raises serious questions about the harm-benefit balance of Rexulti; the Decision may reverse efforts to reduce the use of antipsychotics in US care homes. During testing, the antipsychotic medication brexpiprazole (Rexulti) did not demonstrate a significant therapeutic effect and was

FDA's accelerated drug approvals often lack confirmatory evidence

FDA rushes approval of dementia drug that quadruples risk of death

FDA's Fast-Track for Rexulti Raises Concerns

U.S. FDA Approved Drugs from 2015–June 2020: A Perspective

FDA fast-tracking approval of new drugs — fewer trials, less info

Not Everyone Agreed With FDA Approval of Antipsychotic Rexulti for

Not Everyone Agreed With FDA Approval of Antipsychotic Rexulti for

FDA's Shocking Approval: Rexulti Fast-Tracked Despite Deadly Risks

FDA Takes Tougher Line on Fast-Tracked Drugs - WSJ

Pharm Exec's Emerging Pharma Leaders 2016

Drug Trials Snapshots: REXULTI